Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | RPLP1 | P05386 | 1/20 | 0.35 |
| ▸ | RPLP0 | P05388 | 1/20 | 0.35 |
| ▸ | RPS17 | P08708 | 1/20 | 0.35 |
| ▸ | RPSA | P08865 | 1/20 | 0.35 |
| ▸ | RPS2 | P15880 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3319287 | 0.88 | HCAR2 (0.46) | HCAR2NAPRTSPRPROKR1RBP4 | |
| SCHEMBL23235688 | 0.85 | HCAR2 (0.47) | HCAR2NAPRTSPRRBP4RPLP1 | |
| SCHEMBL2596096 | 0.79 | POLB (0.47) | HCAR2PDE10AGRM1 | |
| SCHEMBL2595721 | 0.79 | PDE10A (0.62) | PDE10A | |
| SCHEMBL3320639 | 0.79 | PDE10A (0.47) | PDE10APROKR1HSD11B1 | |
| SCHEMBL15529677 | 0.78 | NPC1 (0.52) | CYP2C9 | |
| SCHEMBL3321668 | 0.77 | PROKR1 (0.51) | PDE10APROKR1 | |
| SCHEMBL2546639 | 0.75 | HCAR2 (0.49) | HCAR2NAPRTCYP2C19P2RX7 | |
| SCHEMBL2546634 | 0.75 | HCAR2 (0.49) | HCAR2NAPRTCYP2C19P2RX7 | |
| SCHEMBL3319484 | 0.75 | KDM4E (0.48) | PDE10ASPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718803-B2 | Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors | AMGEN INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2569300-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143365-A1 | NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | HCAR2 1256/4885NAPRT 438/4885PDE10A 1/4885 |
| US-20160102075-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | HCAR2 1256/4885NAPRT 438/4885PDE10A 1/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | HCAR2 1256/4885NAPRT 438/4885PDE10A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.